K. J. Smith, H. G. Skelton, J. Yeager, R. Ledsky, W. McCarthy, D. Baxter, et al., “Cutaneous Findings in HIV-1-Positive Patients: A 42-Month Prospective Study, Military Medical Consortium for the Advancement of Retroviral Research,” Journal of the American Academy of Dermatology, Vol. 31, No. 5, 1994, pp. 746-754. doi:10.1016/S0190-9622(94)70236-5

has been cited by the following article:

• TITLE: Melanonychia in Patients Infected with Human Immunodeficiency Virus Original Communication

  AUTHORS: Parvaneh Ehsanzadeh-Cheemeh, Richard M. Grimes, Paul Rowan, Yu-Jing Huang, E. James Essien, Stanley T. Lewis

  KEYWORDS: Zidovudine, Stavudine, Melanonychia, HIV/AIDS, Skin Pigmentation

  JOURNAL NAME: Advances in Infectious Diseases, Vol.1 No.2, December 21, 2011

  ABSTRACT: This study examined whether melanonychia was more prevalent in 1) HIV positive individuals compared to HIV negative persons, 2) HIV positives exposed to zidovudine and/or stavudine and 3) those with darker skin pigmentation. Procedures. 267 HIV positive and 273 HIV negative patients were examined for presence or absence of melanonychia and level of skin pigmentation using the Fitzgerald scale. Pharmacy records were examined for determining exposure to zidovudine or stavudine. Chi square, odds ratios and logistic regression were used to examine the study questions Main Findings. Melanonychia appeared in 49.1% of 267 HIV positive and 21.8% of 273 HIV negative subjects. Adjusting for skin pigmentation, HIV positives were 4.1 times more likely to have melanonychia than HIV negatives. Melanonychia was present in 54% of those receiving zidovudine and in 42% of those receiving stavudine (OR = 2.73, p = 0.05). In a multivariate model in HIV positives which included skin type, prescription of zidovudine and/or Stavudine, only dark skin (OR = 14.62, p